# Promentis Pharmaceuticals

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/promentis-pharmaceuticals

- Industry: Biotechnology
- Headquarters: Milwaukee, US
- Website: www.promentispharma.com
- Total disclosed funding: $17M
- Latest round: Series C (Mar 30, 2017)
- Investors on record: 5

## About

Promentis Pharmaceuticals, Inc. is dedicated to developing innovative therapies for neuropsychiatric disorders, focusing on addressing critical imbalances in neurotransmission with its lead product, SXC-2023.Founded in 2007, Promentis Pharmaceuticals, Inc. is based in Milwaukee, US. The company focuses on developing treatments for neuropsychiatric disorders. Its founders, David Baker and John Mantsch, have a history in the pharmaceutical domain. The most recent funding round occurred on December 10, 2019, raising USD 2.5 mn, which is the total amount raised to date. Promentis has been involved in 9 different deals throughout its history.Promentis Pharmaceuticals, Inc. focuses on developing innovative therapies aimed at addressing neuropsychiatric disorders, with its core product being SXC-2023. This compound is designed to engage the System x c - target, which plays a crucial role in restoring glutamatergic neurotransmission and addressing oxidative stress imbalances—both significant contributors to impaired cortical function in various CNS disorders. The initial indication for SXC-2023 is trichotillomania, a prevalent condition that affects millions yet lacks FDA-approved treatments. The company's product offerings are primarily targeted towards healthcare providers, mental health professionals, and ultimately, patients suffering from neuropsychiatric disorders, with a commitment to serve markets in North America and Europe where there is a significant unmet medical need.Details regarding the revenue structure of Promentis Pharmaceuticals, Inc. are centered around the development and potential commercialization of its lead compound, SXC-2023. The company engages in business transactions primarily through partnerships with healthcare providers and institutions, potentially involving direct sales to these organizations once products are approved. The proposed structure may include collaborations with clinical research organizations or pharmaceutical companies for joint development, as well as future sales arrangements where healthcare providers obtain the product for their patients. Pricing plans and specific costs for SXC-2023 or any other services are established in accordance with the regulatory landscape and market conditions, with an emphasis on facilitating access to treatments for patients in need, particularly in underserved therapeutic areas.Promentis Pharmaceuticals, Inc. is focused on advancing its lead compound, SXC-2023, with plans for upcoming clinical trials. The company is exploring expansion into European markets, aiming for a presence by 2023. The recent funding of USD 2.5 mn will be utilized to support the development of SXC-2023 and to facilitate market entry initiatives.

## Funding rounds

- Series C, Mar 30, 2017, $17M — OrbiMed Advisors, Aisling Capital, F-Prime Capital, Black Horse Investments, Golden Angels Investors

## Investors

- OrbiMed Advisors (https://capitalatlas.ai/funds/orbimed-advisors) — Series C
- Aisling Capital (https://capitalatlas.ai/funds/aisling-capital) — Series C
- F-Prime Capital (https://capitalatlas.ai/funds/f-prime-capital) — Series C
- Black Horse Investments — Series C
- Golden Angels Investors (https://capitalatlas.ai/funds/golden-angels-investors) — Series C